Transjugular intrahepatic portosystemic shunt for hepatorenal syndrome: A systematic review and meta-analysis - PubMed (original) (raw)
Review
. 2018 Apr;50(4):323-330.
doi: 10.1016/j.dld.2018.01.123. Epub 2018 Feb 17.
Affiliations
- PMID: 29422242
- DOI: 10.1016/j.dld.2018.01.123
Review
Transjugular intrahepatic portosystemic shunt for hepatorenal syndrome: A systematic review and meta-analysis
Tingxue Song et al. Dig Liver Dis. 2018 Apr.
Abstract
Background: Hepatorenal syndrome is a severe complication of advanced liver diseases with a dismal prognosis.
Aims: This systematic review and meta-analysis aims to explore the efficacy and safety of transjugular intrahepatic portosystemic shunt for the treatment of hepatorenal syndrome.
Method: Publications were searched via PubMed and EMBASE databases. The pooled proportion and mean difference were calculated by using a random-effect model.
Results: Nine publications were included, in which 128 patients with hepatorenal syndrome were treated with transjugular intrahepatic portosystemic shunt. The pooled short-term and 1-year survival rates were 72% and 47% in type 1 hepatorenal syndrome and 86% and 64% in type 2 hepatorenal syndrome. No lethal procedure-related complications were observed. The pooled rate of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt was 49%. The pooled rate of renal function improvement after transjugular intrahepatic portosystemic shunt was 93% in type 1 hepatorenal syndrome and 83% in any type of hepatorenal syndrome. After transjugular intrahepatic portosystemic shunt, serum creatinine, blood urea nitrogen, serum sodium, sodium excretion, and urine volume were significantly improved; by comparison, serum bilirubin slightly increased, but the difference was not statistically significant.
Conclusion: Limited evidence suggested a potential survival benefit of transjugular intrahepatic portosystemic shunt in patients with hepatorenal syndrome but with a high incidence of hepatic encephalopathy.
Keywords: Hepatorenal syndrome; Liver cirrhosis; Renal function; Terlipressin; Transjugular intrahepatic portosystemic shunt.
Copyright © 2018 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
Similar articles
- Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
Testino G, Ferro C, Sumberaz A, Messa P, Morelli N, Guadagni B, Ardizzone G, Valente U. Testino G, et al. Hepatogastroenterology. 2003 Nov-Dec;50(54):1753-5. Hepatogastroenterology. 2003. PMID: 14696397 - Transjugular intrahepatic portosystemic shunt and alfapump® system for refractory ascites in liver cirrhosis: Outcomes and complications.
Will V, Rodrigues SG, Stirnimann G, Gottardi A, Bosch J, Berzigotti A. Will V, et al. United European Gastroenterol J. 2020 Oct;8(8):961-969. doi: 10.1177/2050640620938525. Epub 2020 Jun 26. United European Gastroenterol J. 2020. PMID: 32588789 Free PMC article. - Transjugular intrahepatic portosystemic shunt in the management of ascites and hepatorenal syndrome.
Senzolo M, Cholongitas E, Tibballs J, Burroughs A, Patch D. Senzolo M, et al. Eur J Gastroenterol Hepatol. 2006 Nov;18(11):1143-50. doi: 10.1097/01.meg.0000236872.85903.3f. Eur J Gastroenterol Hepatol. 2006. PMID: 17033432 Review. - [The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension].
Fang DC, Chen L. Fang DC, et al. Zhonghua Gan Zang Bing Za Zhi. 2009 Apr;17(4):244-6. Zhonghua Gan Zang Bing Za Zhi. 2009. PMID: 19403016 Chinese. No abstract available. - Transjugular Intrahepatic Portosystemic Shunts: Advances and New Uses in Patients with Chronic Liver Disease.
Boike JR, Flamm SL. Boike JR, et al. Clin Liver Dis. 2020 Aug;24(3):373-388. doi: 10.1016/j.cld.2020.04.007. Epub 2020 May 31. Clin Liver Dis. 2020. PMID: 32620278 Review.
Cited by
- Effects of Transjugular Intrahepatic Portosystemic Shunt on Renal and Pulmonary Function in Hepatic Decompensation with and without Hepatorenal and Hepatopulmonary Syndromes: A Review.
Abdelwahed AH, Aboeldahb M, Wu GY. Abdelwahed AH, et al. J Clin Transl Hepatol. 2024 Sep 28;12(9):780-791. doi: 10.14218/JCTH.2024.00188. Epub 2024 Jul 25. J Clin Transl Hepatol. 2024. PMID: 39280072 Free PMC article. Review. - The Role of Transjugular Intrahepatic Portosystemic Shunt for the Management of Ascites in Patients with Decompensated Cirrhosis.
Iannone G, Pompili E, De Venuto C, Pratelli D, Tedesco G, Baldassarre M, Caraceni P, Zaccherini G. Iannone G, et al. J Clin Med. 2024 Feb 27;13(5):1349. doi: 10.3390/jcm13051349. J Clin Med. 2024. PMID: 38592162 Free PMC article. Review. - Recent developments in the management of ascites in cirrhosis.
Lan T, Chen M, Tang C, Deltenre P. Lan T, et al. United European Gastroenterol J. 2024 Mar;12(2):261-272. doi: 10.1002/ueg2.12539. Epub 2024 Feb 10. United European Gastroenterol J. 2024. PMID: 38340308 Free PMC article. Review. - Role of Transjugular Intrahepatic Portosystemic Shunt in the Liver Transplant Setting.
Di Cola S, Lapenna L, Gazda J, Fonte S, Cusi G, Esposito S, Mattana M, Merli M. Di Cola S, et al. J Clin Med. 2024 Jan 21;13(2):600. doi: 10.3390/jcm13020600. J Clin Med. 2024. PMID: 38276106 Free PMC article. Review. - Hepatorenal Syndrome-Novel Insights into Diagnostics and Treatment.
Badura K, Frąk W, Hajdys J, Majchrowicz G, Młynarska E, Rysz J, Franczyk B. Badura K, et al. Int J Mol Sci. 2023 Dec 14;24(24):17469. doi: 10.3390/ijms242417469. Int J Mol Sci. 2023. PMID: 38139297 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical